News

The Financial Burden of Eye Disease

Ellen Troyer, MT MA Biosyntrx CEO/Chief Research Officer May 11, 2012 The National Eye Institute (NEI) estimates that the current annual cost of vision impairment and degenerative eye disease to the United States private and public sector exceeds $68 billion. And this number does not fully quantify the impact of lost productivity, diminished quality of [Read More]

What Is Macular Degeneration?

by Dan Roberts (Updated 9/12/2023) Audio/visual presentations on all related subjects Recommended books: The First Year: Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts Macular Degeneration: The Complete Guide to Saving and Maximizing Your Sight by Lylas Mogk, M.D. and Marja Mogk, Ph.D. Definition Age-related macular degeneration (AMD) is [Read More]

New Radiation Treatment for Wet AMD

by Dan Roberts [It was reported on 2/9/12 that Phase III of this study did not meet it’s primary endpoint at 2 years. The information in this article describes the progress up to that point.] NeoVista, Inc. announced on June 17, 2007 the official commencement of the CABERNET (Cnv secondary to Amd treated with BEta [Read More]

New Treatment for Dry AMD Using HuCNS Stem Cells

by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single [Read More]